Skip over main navigation
  • Log in
  • Basket: (0 items)
Emerge Australia
  • Twitter
  • Facebook
  • Email
Donate Become a member
Menu
  • About us
    • What we do
    • Our team
    • Our Ambassador
    • Our impact
    • Annual reports
    • Position Statements
    • Contact us
  • ME/CFS information
    • ME/CFS Information
    • Long COVID
    • Post-Exertional Malaise
    • Management
    • For health professionals
    • For carers
    • Member stories
  • Research
    • ME/CFS biobank and registry
    • Research Digest
    • Health and Wellbeing Survey
  • How to get help
    • Patient Support and Information Services
    • Telehealth Nurse Service
    • Online Community
    • GP Education Program
    • Accessing financial support
      • About NDIS
      • About DSP
      • NDIS and DSP Application Resources
  • Get involved
    • Give monthly
    • Donate
    • Fundraisers
    • Bequest giving
    • Emerge Australia Membership
    • Volunteer with us
    • Patient Advisory Group
    • Campaigns and advocacy resources
    • ME/CFS Awareness Week
  • Forum
  • News
  • Admin
    • Log in
  • Basket: (0 items)
  • Research Digest 26/05/22

    Research Digest 26/05/22

    Welcome to the Research Digest’s 84th edition. This month we recap research studies of ME/CFS endothelial cell dysfunction and how metabolomics may provide insight into ME/CFS, pre-and post-exercise. Also presented, is advice for the treatment of Long Covid patients, given the injustices experienced by those with ME/CFS and a very honest account of what lengths a person living with ME/CFS will go to, in the absence of ME/CFS treatments; accenting the dire need for vital ME/CFS research funding. Read more

  1. Home
  2. Research Digest

Research Digest

You can also join our community and choose to have the Research Digest delivered straight to your inbox every month on a Friday afternoon by signing up to our mailing list here.

We appreciate the support of everyone who reads the Research Digest – we encourage regular subscribers to support us with a suggested donation of $2. You can donate here.

Research Digest 26/05/22

Research Digest 26/05/22

Welcome to the Research Digest’s 84th edition. This month we recap research studies of ME/CFS endothelial cell dysfunction and how metabolomics may provide insight into ME/CFS, pre-and post-exercise. Also presented, is advice for the treatment of Long Covid patients, given the injustices experienced by those with ME/CFS and a very honest account of what lengths a person living with ME/CFS will go to, in the absence of ME/CFS treatments; accenting the dire need for vital ME/CFS research funding. Read more

Published: 26th May, 2022

Author: Michelle Tavoletti

Research Digest 28/04/22

Research Digest 28/04/22

Welcome to the 83rd edition of the Research Digest. This month’s edition features ME/CFS studies focused on orthostatic intolerance, the effects of Naltrexone on ME/CFS NK cells, as well as a promising ME/CFS eye movement diagnostic tool. This edition also highlights Emerge Australia’s radio interviews featuring Anne Wilson, our CEO campaigning for an update to the ME/CFS guidelines and Richard Schloeffel (our Medical Director) calling out the disbelief of ME/CFS as “Medical Abuse Syndrome”. Read more

Published: 28th April, 2022

Updated: 25th May, 2022

Author: Michelle Tavoletti

Research Digest 24/03/22

Research Digest 24/03/22

Welcome to the 82nd edition of the Research Digest. This month’s edition features studies investigating blood flow abnormalities that may contribute to the pathogenesis of ME/CFS and how lessons learnt from heat stroke may be useful to better understand ME/CFS. Further analysis of Long Covid and its overlap with ME/CFS symptomology is also presented with future research areas postulated. And last but not least, we present highlights from Anne Wilson’s recent radio interview on ABC Life Matters, Read more

Published: 24th March, 2022

Updated: 28th April, 2022

Author: Michelle Tavoletti

Research Digest 24/02/22

Welcome to the 81st edition of the Research Digest. This edition reviews research articles investigating the potential of the cortical autonomic network, to act as a therapeutic target for ME/CFS symptom management, the involvement of C1q in ME/CFS pathology and more evidence demonstrating a linkage between ME/CFS and Long Covid. The highlights from a radio interview featuring Emerge Australia’s CEO Anne Wilson on 2GB, are also presented. Read more

Published: 24th February, 2022

Updated: 25th May, 2022

Author: Michelle Tavoletti

Research Digest 23/12/21

Welcome to the 80th edition of the Research Digest. This edition summarises research papers trialling CT38s to investigate the involvement of the corticotropin-releasing factor system in ME/CFS and an Australian study observing the impact of life stressors, on those living with ME/CFS. The 80th and final edition of the research digest is concluded for 2021, with Emerge Australia’s full-page advertisement in the AFR, providing ME/CFS a voice in the national Long COVID conversation. Read more

Published: 23rd December, 2021

Updated: 28th April, 2022

Author: Michelle Tavoletti

Research Digest 26/11/21

Welcome to the 79th edition of the Research Digest. This month’s edition of the research digest presents an article distinguishing ME/CFS patients based upon herpesviruses serology and also a comprehensive examination of severely ill ME/CFS patients.  The 79th edition also highlights a review paper discussing redox imbalance and how this contributes to biological abnormalities that have long been known for ME/CFS, but now are also being observed in patients with acute and Long COVID. Read more

Published: 26th November, 2021

Updated: 24th March, 2022

Author: Michelle Tavoletti

Research Digest 29/10/21

Welcome to the 78th edition of the Research Digest. This edition of the research digest features articles investigating ACE2 gene expression in ME/CFS blood cells and findings from a UK audit of doctors knowledge and experience with ME/CFS.  This edition also highlights recent reports in the media, articulating links between long-COVID and ME/CFS. Read more

Published: 29th October, 2021

Updated: 24th February, 2022

Author: Michelle Tavoletti

Research Digest 24/09/21

Welcome to the 77th edition of the Research Digest. This edition of the digest presents articles exploring the feasibility of N-of-1 observational design for the study of ME/CFS, and attribution theory to investigate the relationship between higher perceived stigma and lower functional status found in ME/CFS. Read more

Published: 23rd September, 2021

Updated: 21st December, 2021

Author: Michelle Tavoletti

Research Digest 10/09/21

Welcome to the 76th edition of the Research Digest. This edition features articles describing the potential therapeutic benefit of low dose Naltrexone in ME/CFS and a pilot eLORETA study examining the central autonomic network involvement in PEM in ME/CFS. Read more

Published: 10th September, 2021

Updated: 23rd June, 2022

Author: Michelle Tavoletti

Load more Back to top

Showing 10 of 84

Latest

  • Our GPs need to know what to do: We have the plan, we need the funds

    Our GPs need to know what to do: We have the plan, we need the funds

    Emerge Australia has written a 5 years plan for GP Education about ME/CFS, Long COVID and post-viral diseases, accessible to all of Australia’s GPs.

  • What will it take for Australia to get new clinical guidelines for ME/CFS?

    What will it take for Australia to get new clinical guidelines for ME/CFS?

    $1,200,000 is required over 2 years for the development of national clinical guidelines for ME/CFS It is a matter of urgency for Australia to update its clinical guidelines for ME/CFS, to ensure Australian ME/CFS patients have access to the best possible care, based on current understanding of the condition and latest evidence.

  • Australians with ME/CFS need Optimal Care Pathways

    Australians with ME/CFS need Optimal Care Pathways

    $1,100,000 is required over 5 years for an Optimal Care Pathway for ME/CFS. Optimal Care Pathways (OCP) support integrated shared care across the entire health system. Such innovative approaches to the coordination of non-clinical service delivery have achieved improved outcomes for patients in other settings.

  • Changes to the Support and Services programs

    Changes to the Support and Services programs

    With the completion of our Patient Pathways telehealth pilot program on June 30, 2022 we will be making some changes to how the service works and the programs it delivers.

Most read

  • What is ME/CFS?

    What is ME/CFS?

    Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex and disabling disease that affects many parts of the body, including the brain and muscles, as well as the digestive, immune and cardiac systems, among others.

  • Contact Us

    Contact Us

    Emerge Australia provides an information line where you can find out about the latest news and information about ME/CFS.

  • What we do

    What we do

    Who we are and what we do

  • Volunteer with us

    Volunteer with us

    Join our small, friendly and enthusiastic team as a volunteer

  • How is functional impairment assessed?

  • Coronavirus and ME - Simplified facts

    Coronavirus and ME - Simplified facts

    Many people with ME/CFS and other vulnerable communities in Australia are concerned about the impacts of the spreading coronavirus disease COVID-19. This is an easy-read resource with the latest information and advice.

  • Annual reports

    Annual reports for Emerge Australia

  • Symposium

    Replace this with your content

  • Patient Advisory Group

    Patient Advisory Group

    The Patient Advisory Group provides Emerge Australia with ongoing advice about the needs of the community, as well as invaluable input into projects

  • What is ME/CFS?

    What is ME/CFS?

    Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex and disabling disease that affects many parts of the body, including the brain and muscles, digestive, immune and cardiac systems. ME is classified as a neurological disorder by the World Health Organization.

Sign up to our newsletter

* indicates required


Specific mailing lists

Helpful links

  • Sitemap
  • Accessibility
  • Terms & Conditions
  • Privacy Policy

Connect with us

  • Twitter
  • Facebook
  • YouTube


Get in touch with us

Emerge Australia
Level 7, 276 Flinders Street
Melbourne VIC 3000
1800 865 321
03 9529 1344
Media enquiries: 0400 165 391
 

Emerge Australia is registered as a charity with the Australian Charities and Not-for-profits Commission (ACNC). We are authorised by the Australian Tax Office as a deductible gift recipient (DGR). 

ABN/DGR: 22 385 438 041

Donations of $2 or more are tax-deductible. 

Emerge Australia acknowledges Aboriginal and Torres Strait Islander people as the Traditional Custodians of the land and pays respect to their Elders past and present.

© 2019 Emerge Australia. All rights reserved.